Dr. Gholami is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2335 Stockton Blvd.
NAOB 6118
Sacramento, CA 95817Phone+1 916-734-2843Fax+1 916-703-5267
Summary
- I am a board-certified surgeon scientist with dual fellowship training in Complex General Surgical Oncology and Hepatopancreatobiliary Surgery. I specialize in surgeries of the gastrointestinal tract, liver, biliary tree, and the pancreas. My clinical interests include innovative approaches to cancer care including minimally invasive surgery and robotic techniques as well as liver-directed therapies/regional therapies in patients with hepatobiliary and metastatic malignancies. My research focus includes translational science and clinical trials to advance the understanding of hepatobiliary and pancreas tumor genetics, microenvironment, and immune profiling.
Education & Training
- University of California, Davis Medical CenterMAS, Clinical Research, 2019
- Memorial Sloan Kettering Cancer CenterFellowship, Complex General Surgical Oncology, 2015 - 2017
- Stanford Health Care-Sponsored Stanford UniversityResidency, Surgery, 2008 - 2015
- Stanford University School of MedicineClass of 2008
Certifications & Licensure
- NY State Medical License 2010 - 2025
- CA State Medical License 2009 - 2023
- MO State Medical License 2017 - 2018
- American Board of Surgery Surgery
- American Board of Surgery Complex General Surgical Oncology
Awards, Honors, & Recognition
- Fellow (FACS) American College of Surgeons
Publications & Presentations
PubMed
- Reply to: Should Total Neoadjuvant Therapy Be the First-Line Treatment for Patients With Locally Advanced Rectal Cancer?Aaron J Scott, Erin B Kennedy, Sepideh Gholami
Journal of Clinical Oncology. 2025-01-06 - Trastuzumab Plus Pertuzumab Versus Cetuximab Plus Irinotecan in Patients WithWild-Type, HER2-Positive, Metastatic Colorectal Cancer (S1613): A Randomized Phase II Trial.Kanwal Pratap Singh Raghav, Katherine A Guthrie, Benjamin Tan Jr, Crystal S Denlinger, Marwan Fakih
Journal of Clinical Oncology. 2025-01-06 - Factors Influencing Immunotherapy Utilization in Stage IV Pancreatic Cancer: Impact of Race and Socioeconomics in the U.S.Abdullah Khalid, Zohaa Faiz, Manav Shah, Elliot Newman, Daniel A King
Journal of Gastrointestinal Cancer. 2024-11-27
Journal Articles
- Size and Location Are the Most Important Risk Factors for Malignant Behavior in Resected Solitary Fibrous TumorsSepideh Gholami, Amanda Kirane, Murray Brennan, Annals of Surgical Oncology
Books/Book Chapters
Press Mentions
- Organoids May Predict Effective Chemotherapy TreatmentApril 6th, 2022
- First-in-Region Targeted Liver Cancer Therapy Gives Patients New HopeNovember 24th, 2021
- Abdominal Pain Isn’t Normal and Shouldn’t Be Ignored (Video)March 12th, 2021
Professional Memberships
- Member
Other Languages
- French, Farsi, German
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: